Abstract
Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Current Drug Therapy
Title:Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study
Volume: 8 Issue: 3
Author(s): Philippe Bareille, Ann Allen, Kelly Hardes and Alison Donald
Affiliation:
Keywords: Allergen challenge, early asthmatic response, GW870086, late asthmatic response.
Abstract: Aim: The objective was to assess the effect of inhaled doses of GW870086, a novel selective corticosteroid, on allergen-induced early and late asthmatic responses (EAR/LAR).
Methods: Twenty-four males with mild asthma were randomised in a double-blind, three-way crossover study to receive GW870086 0.25 mg, 1 mg and 3 mg once-daily, fluticasone propionate (FP) 0.25 mg twice-daily or placebo for 13 days.
Results: Change from baseline in weighted mean LAR (95% CI) were -0.340 L (-0.567, -0.113), -0.396 L (-0.626, -0.167) and -0.248 L (-0.471,-0.024) for GW870086 0.25 mg, 1 mg and 3 mg, respectively, -0.146 L (-0.371, 0.078) for FP 0.25 mg and -0.550 L (-0.744, -0.356) for placebo. Reductions (vs. placebo) for GW870086 0.25 mg and 3 mg, and FP 0.25 mg achieved statistical significance. GW870086 3 mg demonstrated attenuation of the weighted mean EAR (- 0.634 L [-0.885; -0.383]); however, compared with placebo this was not significant. Methacholine PC20 was significantly increased (vs. placebo) after GW870086 3 mg and FP 0.25 mg. Exhaled NO was reduced (vs. placebo), achieving statistical significance after all treatments.
Conclusion: GW870086 3 mg demonstrated anti-inflammatory activity and offered protection from airway hyperresponsiveness.
Export Options
About this article
Cite this article as:
Bareille Philippe, Allen Ann, Hardes Kelly and Donald Alison, Effect of a Novel Selective Inhaled Steroid on the Allergen-Induced Early and Late Asthmatic Response in Adults with Mild Asthma: A Randomised Study, Current Drug Therapy 2013; 8 (3) . https://dx.doi.org/10.2174/15748855113089990005
DOI https://dx.doi.org/10.2174/15748855113089990005 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Divergent Roles of IRS (Insulin Receptor Substrate) 1 and 2 in Liver and Skeletal Muscle
Current Medicinal Chemistry Rho-Kinase as a Drug Target for the Treatment of Airway Hyperresponsiveness in Asthma
Mini-Reviews in Medicinal Chemistry IgE-Binding Epitope Analysis of Bla g 5, the German Cockroach Allergen
Protein & Peptide Letters Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets Update on Sensitivity to Nonsteroidal Antiinflammatory Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Editorial (Thematic Issue: Biomarkers of Impaired Innate and Adaptive Immunity in Health and Disease)
Current Immunology Reviews (Discontinued) Targeting the Prostaglandin D2 Receptors DP and CRTH2 for Treatment of Inflammation
Current Topics in Medicinal Chemistry Personalized Drug Therapy in Cystic Fibrosis: From Fiction to Reality
Current Drug Targets The Effect of Flavonoids on Allergic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-Angiogenetic Agents from the Sea: A New Potential Preventive and Therapeutic Wave?
Anti-Cancer Agents in Medicinal Chemistry Interleukin-10
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Flexible Bronchoscopy Biopsy Tools and Techniques to Optimize Diagnostic Yield: A Contemporary Review
Current Respiratory Medicine Reviews CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Pneumonia in the Elderly
Current Respiratory Medicine Reviews Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Polyphenols and Depression: from Chemistry to Medicine
Current Pharmaceutical Biotechnology Adrenomedullin as a Potential Therapeutic Agent for Inflammatory Bowel Disease
Current Protein & Peptide Science Inhaled Corticosteroids in Asthmatic Children: Are They as Safe in Infants and Preschoolers as in Older Children? A Review
Current Drug Safety Meet Our Editorial Board Member
Current Medicinal Chemistry Analyses of Associations Between Reactive Oxygen Metabolites and Antioxidant Capacity and Related Factors Among Healthy Adolescents
Current Aging Science